We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Bluejay Diagnostics Inc (BJDX) USD0.0001

Sell:$3.75 Buy:$3.92 Change: $0.05 (1.32%)
Market closed |  Prices as at close on 26 December 2024 | Switch to live prices |
Sell:$3.75
Buy:$3.92
Change: $0.05 (1.32%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 26 December 2024 | Switch to live prices |
Sell:$3.75
Buy:$3.92
Change: $0.05 (1.32%)
Market closed |  Prices as at close on 26 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a rapid, near-patient testing system for triage and monitoring of disease progression. Its product candidate, an IL-6 Test for sepsis triage, is designed to provide results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and better triage/treatment decisions. The Symphony platform is a combination of its intellectual property (IP) and exclusively licensed and patented IP that consists of a mobile device and single-use test cartridges. The Symphony platform and its initial biomarker test, Symphony IL-6 test, is suited to address a subset of the global in vitro diagnostics devices market, including sepsis, cardio-metabolic diseases, cancer and other diseases that require rapid tests. Symphony targets critical care markets where physicians must quickly determine patient acuity to identify optimal treatment regimens.

Contact details

Address:
360 Massachusetts Avenue, Suite 203
ACTON
01720
United States
Telephone:
+1 (978) 6310152
Website:
https://bluejaydx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
BJDX
ISIN:
US0956335097
Market cap:
$2.10 million
Shares in issue:
552,854
Sector:
Health Care Equipment
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Neil Dey
    President, Chief Executive Officer, Co-Founder, Principal Financial and Accounting Officer, Director
  • Jason Cook
    Chief Technology Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.